Amaro Therapeutics, Inc.
October 15, 2024
California Room
Metabolic Diseases
Amaro Therapeutics is an early-stage therapeutic platform company focused on the activation of ubiquitously expressed chemosensory receptors (TAS2R), as therapeutic targets, for the treatment of human diseases and conditions - particularily diseases of aging including CNS disorders, COPD, diabetes, fibrosis, obesity (activation of GLP-1 and CCK), sarcopenia, etc..
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}